Korean vaccine developer EuBiologics said it has published the phase 3 multinational clinical trial results for its typhoid conjugate vaccine, EuTYPH C Inj., in the December issue of the Lancet Global Health.
The study, conducted in Senegal and Kenya with 2,219 participants aged six months to 45 years, demonstrated clear immunological non-inferiority compared to Typbar TCV, a World Health Organization (WHO) prequalification vaccine.
The trial was carried out in collaboration with the international health organization PATH and funded by the RIGHT Foundation.
The company expects that the findings carry significant global credibility because the research was conducted directly in African countries where the vaccine is expected to be supplied.
According to the paper, seroconversion rates in infants aged nine to twelve months reached 99.6 to 100 percent on day 28, showing responses equivalent to or better than those seen with the WHO prequalified comparator. No serious adverse events were reported in either group.
EuBiologics obtained export approval for EuTYPH C inj. from Korea’s Ministry of Food and Drug Safety (MFDS) earlier this year and submitted its WHO prequalification application in May. The review is underway.
If approved, the vaccine will be eligible for Gavi and UNICEF procurement, enabling full-scale supply as early as the second half of 2026. The company has also participated in UNICEF awards and tender processes since August.
Typhoid fever affects more than seven million people globally each year and remains a major infectious disease in low income regions.
Demand for typhoid conjugate vaccines has been rising particularly in Africa and South Asia. EuTYPH C inj. is built on EuBiologics’ proprietary CRM197 carrier protein and produced using a high efficiency conjugation and manufacturing system that the company says provides a cost advantage over competing vaccines.
EuBiologics has already supplied more than 200 million doses of its Euvichol oral cholera vaccine series through UNICEF procurement channels.